Global Osteoporosis Drugs Market to Grow at 3.98% During 2025-2033, Spurred by Development of Enhanced Drugs

January 03, 2025 | Healthcare

According to the latest report by IMARC Group, titled "Osteoporosis Drugs Market Report by Product Type (Bisphosphonates, Calcitonin, Rank Ligand Inhibitor, Parathyroid Hormone Therapy (PTH), Selective Estrogen Receptor Modulators (SERMs), Sclerostin Inhibitor, and Others), Route of Administration (Oral, Injectable, and Others), and Region 2025-2033," the global osteoporosis drugs market reached a value of USD 17.3 Billion in 2024. Osteoporosis refers to a medical condition that weakens the bone tissues, rendering them brittle and prone to sudden and unexpected fractures. Characterized by lower bone mass, it can cause deterioration of strength in the hip, spine or wrist. It can be diagnosed with the help of X-ray scans, computed tomography (CT) and magnetic resonance imaging (MRI). Upon detection, various drugs are prescribed to the patient that assist in repairing microscopic defects in bones and minimizing the risk of fractures. These medicines can also be used to restore the balance of resorption and formation, thereby enhancing the overall muscle strength in patients.

Global Osteoporosis Drugs Market Trends:

The global market is majorly driven by the rising prevalence of osteoporosis among the masses. This can be accredited to the increasing consumption of tobacco and alcohol and the lack of physical activities among individuals. The increasing incidences of rheumatoid arthritis and menopause among the female population act as a contributing factor to the escalating number of cases of osteoporosis across the globe. Moreover, there has been a considerable rise in the geriatric population that is more susceptible to developing bone-related disorders, which is creating a positive outlook for the market. This is also supported by the growing awareness among the masses regarding the availability of cost-efficient treatment plans across the healthcare sector. Furthermore, extensive research and development (R&D) activities conducted by players have led to the development of drugs that offer enhanced efficacy. There has also been a rise in the number of pipeline drugs in clinical trials with a high probability of approval in the near future. Coupled with the increasing healthcare expenditure, this is anticipated to create a positive outlook for the market. Looking forward, IMARC Group expects the market to reach USD 25.0 Billion by 2033, exhibiting a growth rate (CAGR) of 3.98% during 2025-2033.

Market Summary:

  • On the basis of the product type, the market is divided into bisphosphonates, calcitonin, rank ligand inhibitor, parathyroid hormone therapy (PTH), selective estrogen receptor modulators (SERMS), sclerostin inhibitor, and others.
  • Based on the route of administration, the market has been classified into oral, injectable and others.
  • On the geographical front, the market has been segregated into North America (the United States and Canada), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia and others), Latin America (Brazil, Mexico and others), and Middle East and Africa.
  • The competitive landscape of the market has been studied in the report with the detailed profiles of the key players. Some of these players include Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Radius Health Inc., Teva Pharmaceutical Industries Ltd., and UCB S.A.


Report Scope:

Report Features Details
Base Year of the Analysis 2024
Historical Period 2019-2024
Forecast Period 2025-2033
Units Billion USD
Segment Coverage Product Type, Route of Administration, Region
Region Covered  Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Radius Health Inc., Teva Pharmaceutical Industries Ltd. and UCB S.A.
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)


About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Group
30 N Gould St, Ste R
Sheridan, WY (Wyoming) 82801 USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Global Osteoporosis Drugs Market to Grow at 3.98% During 2025-2033, Spurred by Development of Enhanced Drugs
Purchase Options New Year Sale
Benefits of Customization
  • Personalize this research
  • Triangulate with your data
  • Get data as per your format and definition
  • Gain a deeper dive into a specific application, geography, customer, or competitor
  • Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials